Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors.
Álvarez Román MT, Kragh N, Guyot P, Wilson A, Wojciechowski P, Margas W, Wdowiak M, Santagostino E, Arnaud A. Álvarez Román MT, et al. Adv Ther. 2025 Jan;42(1):442-455. doi: 10.1007/s12325-024-03031-4. Epub 2024 Nov 22. Adv Ther. 2025. PMID: 39576432 Free PMC article.
The results were analysed to find the overall difference between efanesoctocog alfa and emicizumab. Compared with once-weekly emicizumab, once-weekly efanesoctocog alfa reduced the number of overall bleeds, treated bleeds (additional therapy given to s …
The results were analysed to find the overall difference between efanesoctocog alfa and emicizumab. Compared with once-weekly …
Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews.
DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, Wilson A. DiBenedetti D, et al. Clin Ther. 2024 Dec;46(12):1016-1023. doi: 10.1016/j.clinthera.2024.09.010. Epub 2024 Oct 15. Clin Ther. 2024. PMID: 39414418 Free article. Clinical Trial.
METHODS: In XTEND-1, participants (12 years old) received once-weekly efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks (Arm A) or on-demand efanesoctocog alfa 50 IU/kg for 26 weeks followed by 26 weeks once-weekly prophylaxis (50 IU/kg; Arm B). ... …
METHODS: In XTEND-1, participants (12 years old) received once-weekly efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks (Ar …
Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.
Weyand AC, Meunier S, Suzuki N, Bystrická L, Neill G, Abad-Franch L, Willemze A, Tosetto A. Weyand AC, et al. Am J Hematol. 2025 May;100(5):813-820. doi: 10.1002/ajh.27603. Epub 2025 Feb 10. Am J Hematol. 2025. PMID: 39927501 Free PMC article. Clinical Trial.
In the XTEND-1 study (NCT04161495), once-weekly efanesoctocog alfa (50 IU/kg) prophylaxis provided highly effective bleed prevention and high-sustained factor levels for most of the week and was well-tolerated. ...Results of this analysis further demonstrated that o …
In the XTEND-1 study (NCT04161495), once-weekly efanesoctocog alfa (50 IU/kg) prophylaxis provided highly effective bleed prev …